Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan-Dec:22:15330338231155000.
doi: 10.1177/15330338231155000.

Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH)

L V Sciacqua  1 , A Vanzulli  1 , R Di Meo  1 , G Pellegrino  1 , R Lavorato  2 , G Vitale  3   4 , G Carrafiello  5
Affiliations

Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH)

L V Sciacqua et al. Technol Cancer Res Treat. 2023 Jan-Dec.

Abstract

Review efficacy and safety of minimally-invasive treatments for Low Urinary Tract Symptoms (LUTS) in patients affected by Benign Prostate Hyperplasia (BPH). We performed a systematic review of the literature from 1993 to 2022 leveraging original research articles, reviews, and case-studies published in peer-reviewed journals and stored in public repositories. Prostate artery embolization (PAE), transurethral needle ablation (TUNA), transurethral microwave thermotherapy (TUMT), high intensity focused ultrasound (HIFU), laser treatments and Cryoablation are valid and safe alternatives to the gold standard (surgery) in the treatment of LUTS in patients affected by BPH, with fewer undesired effects being reported.

Keywords: benign prostatic hyperplasia; interventional radiology; low urinary tract symptom; minimal invasive treatments; prostate.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
See this image and copyright information in PMC

References

    1. Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: Epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5(4):212‐218. doi:10.1007/s11884-010-0067-2. - DOI - PMC - PubMed
    1. Oelke M, Bachmann A, Descazeaud A, et al. EAU Guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118‐140. doi:10.1016/j.eururo.2013.03.004. - DOI - PubMed
    1. Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am. 2016;43(3):279‐288. doi:10.1016/j.ucl.2016.04.012. - DOI - PMC - PubMed
    1. Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol. 1994;152(1):115‐119. doi:10.1016/s0022-5347(17)32831-8. - DOI - PubMed
    1. Xia B-W, Zhao S-C, Chen Z-P, et al. Relationship between serum total testosterone and prostate volume in aging men. Sci Rep. 2021;11(1):14122. doi:10.1038/s41598-021-93728-1. - DOI - PMC - PubMed

Publication types